Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02540668 · ClinicalTrials.gov registry record · Phase 1
A Drug Interaction Study of Lanabecestat (LY3314814) and Warfarin in Healthy Participants
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT02540668 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 15 participants.
The verdict
NCT02540668, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
The purpose of this study is to look at how much warfarin gets into the blood stream and how long it takes the body to get rid of it when given both with and without lanabecestat. Another purpose is to evaluate the effectiveness of warfarin therapy to prevent blood clots when given with lanabecestat by measuring international normalized ratio (INR). INR measures the time it takes for blood to clot and compares it to an average. Information about any side effects that may occur will also be collected. The study will last about 5 weeks from the first dose to follow-up for each participant.
Interventions
- DRUG Warfarin
- DRUG Lanabecestat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2015-09-30 |
| Est. Completion | 2016-01-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02540668
The ClinicalTrials.gov registry entry for NCT02540668 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Warfarin is the first listed.
NCT02540668 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02540668 about?
NCT02540668 is a clinical study titled "A Drug Interaction Study of Lanabecestat (LY3314814) and Warfarin in Healthy Participants". The purpose of this study is to look at how much warfarin gets into the blood stream and how long it takes the body to get rid of it when given both with and without lanabecestat. Another purpose is to evaluate the effectiveness of warfarin therapy to prevent blood clots when given with lanabecestat...
What is the current status of trial NCT02540668?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2015-09-30. Estimated completion is 2016-01-31.
What interventions are being tested in trial NCT02540668?
The interventions under investigation include: Warfarin (DRUG), Lanabecestat (DRUG).
Who is sponsoring clinical trial NCT02540668?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.